Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by M101on Feb 01, 2022 1:07pm
165 Views
Post# 34385930

Schizophrenia, +/- ?

Schizophrenia, +/- ? I've been wondering why Cashman's pr comment on schizophrenia seemed a little upbeat, I think it comes down to timing. This 2019 study seems to have opened an avenue for investigation for which our platform is well suited.
https://ictr.johnshopkins.edu/news_announce/physical-evidence-in-the-brain-for-types-of-schizophrenia/
The parallels with AD are obvious but if there's no prion-like spreading then what's the pathology? That's why we're paying Carsten Korth. 
https://www.neurosciences-duesseldorf.de/fileadmin/redaktion/Kooperationen/iCAN/120713high_res_final_-p94-96_Carsten_Korth.pdf
I like the idea of a therapeutic target that can produce immediate lab results, multiple protein targets and lots of dead rats. I really hate rats.  

<< Previous
Bullboard Posts
Next >>